Premier Alternatives

AnaCardio

Stockholm, Sweden · Founded 2017 · Privately Held (backing)

Developer of therapeutic drugs designed to improve clinical outcomes in cardiac failure. AnaCardio is based in Stockholm, Sweden and was founded in 2017. It was valued at $293 million at its Series B in Sep 2026, the last priced event on record. It has raised $44.2 million across 1 recorded round; the latest was a Series B in Sep 2026.

PMV mark · valuation
$292.9M
Oct 2026
Priced at
its Series B
Sep 2026
Total raised
$44.2M
Last round
Series B
Sep 2026
How much has AnaCardio raised?
$44.2Macross 1 recorded rounds · Sep 2026 – Sep 2026

Most recently, AnaCardio raised an undisclosed amount in its Series B (Sep 2026).

Free account
More of AnaCardio with a free account
  • ·The post-money valuation on its round
  • ·The complete investor list: 13 names
  • ·Watch AnaCardio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

AnaCardio round by round

1 rounds
Sep 2026Series Bundisclosed▮
Novo Holdingslead+ 3 more investors · free account

How much has AnaCardio raised?

AnaCardio has raised $44.2 million in total; 1 of its rounds is on record. The most recent was a Series B in Sep 2026. 1 of the rounds disclosed a post-money valuation.

AnaCardio investors

13 investors are on record for AnaCardio, including Novo Holdings, Innovestor, Industrifonden and Nordic Mentor Network For Entrepreneurship. The Series B in Sep 2026 drew 9 investors.

For fundraisers
Raising for a company like AnaCardio?

13 investors have backed AnaCardio.

See all 13 investors →

Frequently asked about AnaCardio

How much has AnaCardio raised?
AnaCardio has raised $44.2M in total across 1 recorded funding rounds.
Who are AnaCardio's lead investors?
Lead investors in AnaCardio's recorded rounds include Novo Holdings.
When was AnaCardio's last funding round?
AnaCardio's most recent recorded round was Series B in Sep 2026.